About Krystal Biotech (KRYS)

Krystal Biotech Inc (KRYS) is a biotech company that focuses on developing and commercializing gene therapies for patients with dermatological diseases. The company's lead product candidate is KB103, which is designed to treat a rare and debilitating skin disorder called dystrophic epidermolysis bullosa (DEB). DEB is caused by mutations in the COL7A1 gene, which leads to a lack of collagen in the skin. This results in severe blistering and open wounds that can be life-threatening. KB103 aims to provide a functional COL7A1 gene to replace the mutated one, thereby restoring collagen production and improving the health of the skin.

Krystal Biotech's gene therapy platform utilizes a non-replicating herpes simplex virus type 1 (HSV-1) vector to deliver the functional genes into the patient's skin cells. This approach has shown promising results in preclinical and early clinical trials, with KB103 demonstrating significant wound closure and reduced blistering in DEB patients. The company is currently conducting a phase 2 clinical trial for KB103, with preliminary data expected in the near future. If successful, KB103 has the potential to be a transformative therapy for DEB patients, addressing an unmet medical need and improving their quality of life.